Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Shares Issued: 2020-2024

Historic Shares Issued for Relay Therapeutics (RLAY) over the last 3 years, with Sep 2024 value amounting to $218.2 million.

  • Relay Therapeutics' Shares Issued rose 2221.28% to $218.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $244.3 million, marking a year-over-year decrease of 16.84%. This contributed to the annual value of $17.9 million for FY2024, which is 40.92% down from last year.
  • According to the latest figures from Q3 2024, Relay Therapeutics' Shares Issued is $218.2 million, which was up 1,118.99% from $17.9 million recorded in Q1 2024.
  • Relay Therapeutics' Shares Issued's 5-year high stood at $427.1 million during Q3 2020, with a 5-year trough of -$2.9 million in Q4 2021.
  • Over the past 3 years, Relay Therapeutics' median Shares Issued value was $9.4 million (recorded in 2023), while the average stood at $75.8 million.
  • As far as peak fluctuations go, Relay Therapeutics' Shares Issued slumped by 99.79% in 2021, and later spiked by 31,463.19% in 2022.
  • Quarterly analysis of 5 years shows Relay Therapeutics' Shares Issued stood at -$2.5 million in 2020, then declined by 17.15% to -$2.9 million in 2021, then surged by 59.93% to -$1.2 million in 2022, then tumbled by 96.70% to $9.4 million in 2023, then surged by 2,221.28% to $218.2 million in 2024.
  • Its last three reported values are $218.2 million in Q3 2024, $17.9 million for Q1 2024, and $9.4 million during Q3 2023.